The study population will be women between 45 and 65 years old, both ages included, who present a decrease in sexual desire or arousal

Female Sexual Dysfunction

Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.

Patients' data (baseline characteristics, clinical and outcomes) from routine care visits

Instituto Palacios de Salud y Medicina de la Mujer

Observational Study in Real Life to Describe the Libicare® Effectiveness in Female Sexual Dysfunction.

Observational Study in Real Life to Describe the Effectiveness of LIBICARE® in Women With Low Arousal and Sexual Desire Levels.

The effectiveness will be assessed by the increase in the score of the EVAS-M scale that will be provided to patients during routine visits. The increase in the score of the EVAS-M scale ("Escala de Valoración de la Actividad Sexual en la mujer" in Spanish) will be measured by the percentage of women who increase score (score from 2 to 60 points)

The effectiveness will be assessed by the increase in the score of the EVAS-M scale ("Escala de Valoración de la Actividad Sexual en la mujer" in Spanish) that will be provided to patients during routine visits. The increase in the score of the EVAS-M scale will be measured by change / absolute increase (final-baseline difference) of the score (score from 2 to 60 points)

The effectiveness will be assessed by the increase in the score of the EVAS-M scale ("Escala de Valoración de la Actividad Sexual en la mujer" in Spanish) that will be provided to patients during routine visits. The increase in the score of the EVAS-M scale will be measured by change / relative increase (% change / increase over baseline) of the score (from 2 to 60 points)

Evaluation of the 6 domains of the EVAS-M scale ("Escala de Valoración de la Actividad Sexual en la mujer" in Spanish, score from 2 to 60 points) at 2 and 4 months of treatment

Assessment of the safety of LIBICARE® by collecting serious and non-serious adverse events

Evaluation of patient satisfaction with treatment at 2 and 4 months of treatment using a Likert scale

Therapeutic compliance in taking the food supplement at 2 and 4 months of treatment using a Likert scale

Study of the hormonal variation in relation to the values of total testosterone, free testosterone and SHBG, at the beginning, at 2 months and at 4 months of treatment, in those patients in which it is determined by routine care

To evaluate the range of utility of the EVAS-M scale ("Escala de Valoración de la Actividad Sexual en la mujer" in Spanish) in clinical routine care after 4 months of treatment using a 4-points Likert scale

Procare Health Iberia S.L.

1 tablet of placebo/ oral/ 3 times a day for three months

1 tablet of 250mg/ oral/ 3 times a day for three months

Sexual Functions and Problems in the Adult

1 tablet/ oral/ 3 times a day for 90 days

Placebo

1 tablet of 250mg/ oral/ 3 times a day for 90 days

Tribulus terrestris

Santa Casa of Sao Paulo Medical School

Effects of Tribulus Terrestris on Sexual Function in Post-menopausal Women

Study of the Effects of Tribulus Terrestris on Sexuality in Postmenopausal Women

Based the questionnaires Golombok-Rust Inventory of Sexual Satisfaction (GRISS) and Sexual Quotient - female version (SQF).

tribulus lanuginosus/antifungal

Observational Study in Real Life to Describe the Libicare® Effectiveness in Female Sexual Dysfunction.

Effects of Tribulus Terrestris on Sexual Function in Post-menopausal Women

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi